In vitro interactions between farnesol and fluconazole, amphotericin b or micafungin against candida albicans biofilms

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 470-478

  Katragkou, Aspasia ^a,b   Mccarthy, Matthew ^a   Alexander, Elizabeth L ^c   Antachopoulos, Charalampos ^b   Meletiadis, Joseph ^d   Jabra rizk, Mary Ann ^e,f   Petraitis, Vidmantas ^a   Roilides, Emmanuel ^b   Walsh, Thomas J ^a,c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF MARYLAND   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungals; C. albicans; Combinations

Indexed keywords

AMPHOTERICIN B; FARNESOL; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; IN VITRO STUDY; METABOLIC ACTIVITY ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; XTT ASSAY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FARNESOL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL;

EID: 84922453920     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku374     Document Type: Article

References (51)

1. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-92.
2. Albuquerque P, Casadevall A. Quorum sensing in fungi-a review. Med Mycol 2012; 50: 337-45.
3. Kuranda K, Francois J, Palamarczyk G. The isoprenoid pathway and transcriptional response to its inhibitors in the yeast Saccharomyces cerevisiae. FEMS Yeast Res 2010; 10: 14-27.
4. Edwards PA, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 1999; 68: 157-85.
5. Ramage G, Saville SP, Wickes BL et al. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
6. Jabra-Rizk MA, Shirtliff M, James C et al. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res 2006; 6: 1063-73.
7. Mosel DD, Dumitru R, Hornby JM et al. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 2005; 71: 4938-40.
8. Ramage G, Vande Walle K, Wickes BL et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
9. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
10. Hawser SP, Norris H, Jessup CJ et al. Comparison of a 2,3-bis(2-methoxy- 4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998; 36: 1450-2.
11. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357-60.
12. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
13. Meletiadis J, Mouton JW, Meis JF et al. In vitro drug interactionmodeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-17.
14. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953; 3: 285-90.
15. Bliss CI. 2 X 2 Factorial experiments in incomplete groups for use in biological assays. Biometrics 1947; 3: 69-88.
16. Meletiadis J, Pournaras S, Roilides E et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother 2010; 54: 602-9.
17. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
18. Chatzimoschou A, Katragkou A, Simitsopoulou M et al. Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob Agents Chemother 2011; 55: 1968-74.
19. Drusano GL, D'Argenio DZ, Symonds W et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998; 42: 2153-9.
20. Meletiadis J, Verweij PE, TeDorsthorst DT et al. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol 2005; 43: 133-52.
21. Millard PJ, Roth BL, Thi HP et al. Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts. Appl Environ Microbiol 1997; 63: 2897-905.
22. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
23. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
24. Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett 2010; 287: 123-35.
25. Rossignol T, Logue ME, Reynolds K et al. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob Agents Chemother 2007; 51: 2304-12.
26. Kruppa M. Quorum sensing and Candida albicans. Mycoses 2009; 52: 1-10.
27. Han TL, Cannon RD, Villas-Boas SG. The metabolic basis of Candida albicans morphogenesis and quorum sensing. Fungal Genet Biol 2011; 48: 747-63.
28. Davis-Hanna A, Piispanen AE, Stateva LI et al. Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. Mol Microbiol 2008; 67: 47-62.
29. Roman E, Alonso-Monge R, Gong Q et al. The Cek1 MAPK is a short-lived protein regulated by quorum sensing in the fungal pathogen Candida albicans. FEMS Yeast Res 2009; 9: 942-55.
30. Phillips AJ, Crowe JD, Ramsdale M. Ras pathway signaling accelerates programmed cell death in the pathogenic fungus Candida albicans. Proc Natl Acad Sci USA 2006; 103: 726-31.
31. Shirtliff ME, Krom BP, Meijering RA et al. Farnesol-induced apoptosis in Candida albicans. Antimicrob Agents Chemother 2009; 53: 2392-401.
32. Zhu J, Krom BP, Sanglard D et al. Farnesol-induced apoptosis in Candida albicans is mediated by Cdr1-p extrusion and depletion of intracellular glutathione. PLoS One 2011; 6: e28830.
33. Navarathna DH, Hornby JM, Krishnan N et al. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 2007; 75: 1609-18.
34. Navarathna DH, Nickerson KW, Duhamel GE et al. Exogenous farnesol interferes with the normal progression of cytokine expression during candidiasis in a mouse model. Infect Immun 2007; 75: 4006-11.
35. Martins M, Lazzell AL, Lopez-Ribot JL et al. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol 2012; 52: 487-91.
36. Hisajima T, Maruyama N, Tanabe Y et al. Protective effects of farnesol against oral candidiasis in mice. Microbiol Immunol 2008; 52: 327-33.
37. Cordeiro RA, Teixeira CE, Brilhante RS et al. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. Med Mycol 2013; 51: 53-9.
38. Koo H, Hayacibara MF, Schobel BD et al. Inhibition of Streptococcus mutans biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. J Antimicrob Chemother 2003; 52: 782-9.
39. Jabra-Rizk MA, Meiller TF, James CE et al. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006; 50: 1463-9.
40. Gomes F, Leite B, Teixeira P et al. Farnesol as antibiotics adjuvant in Staphylococcus epidermidis control in vitro. Am J Med Sci 2011; 341: 191-5.
41. Pammi M, Liang R, Hicks JM et al. Farnesol decreases biofilms of Staphylococcus epidermidis and exhibits synergy with nafcillin and vancomycin. Pediatr Res 2011; 70: 578-83.
42. Gomes F, Teixeira P, Cerca N et al. Effect of farnesol on structure and composition of Staphylococcus epidermidis biofilm matrix. Curr Microbiol 2011; 63: 354-9.
43. Yu LH, Wei X, Ma M et al. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob Agents Chemother 2012; 56: 770-5.
44. Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob Agents Chemother 2011; 55: 4834-43.
45. Costa V, Moradas-Ferreira P. Oxidative stress and signal transduction in Saccharomyces cerevisiae: insights into ageing, apoptosis and diseases. Mol Aspects Med 2001; 22: 217-46.
46. Longo VD, Liou LL, Valentine JS et al. Mitochondrial superoxide decreases yeast survival in stationary phase. Arch Biochem Biophys 1999; 365: 131-42.
47. Scheper MA, Shirtliff ME, Meiller TF et al. Farnesol, a fungal quorumsensing molecule triggers apoptosis in human oral squamous carcinoma cells. Neoplasia 2008; 10: 954-63.
48. Inglis DO, Sherlock G. Ras signaling gets fine-tuned: regulation of multiple pathogenic traits of Candida albicans. Eukaryot Cell 2013; 12: 1316-25.
49. Svegliati S, Cancello R, Sambo P et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005; 280: 36474-82.
50. Hlavata L, Aguilaniu H, Pichova A et al. The oncogenic RAS2(val19) mutation locks respiration, independently of PKA, in a mode prone to generate ROS. EMBO J 2003; 22: 3337-45.
51. Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem 2014; 6: 77-90.